STOCKHOLM, Nov. 18, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in […]
Tag: BioArctic
New data on lecanemab to be presented at CTAD conference
STOCKHOLM, Nov. 18, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in […]
Invitation to presentation of BioArctic's third quarter report for July – September 2025 on November 13 at 9.30 a.m. CET
STOCKHOLM, Nov. 4, 2025 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for July – September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET. In […]
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed […]
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing USA – English USA – English
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) […]
